Drug therapy has dominated glaucoma management for decades but novel devices are shifting the way this disease is managed adding promising new alternatives to the previously limited treatment continuum. For companies acting in this field, along with and increasing number of VCs targeting opthalmology, this shift marks the beginning of a tremendous new opportunity.
